A detailed history of Jacobs Levy Equity Management, Inc transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,430,533 shares of VNDA stock, worth $7.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,430,533
Previous 1,486,262 3.75%
Holding current value
$7.3 Million
Previous $8.4 Million 20.1%
% of portfolio
0.03%
Previous 0.04%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.61 - $6.34 $256,910 - $353,321
-55,729 Reduced 3.75%
1,430,533 $6.71 Million
Q2 2024

Aug 14, 2024

BUY
$3.91 - $6.5 $260,804 - $433,563
66,702 Added 4.7%
1,486,262 $8.4 Million
Q1 2024

May 15, 2024

SELL
$3.47 - $4.61 $35,706 - $47,436
-10,290 Reduced 0.72%
1,419,560 $5.83 Million
Q4 2023

Feb 14, 2024

BUY
$3.38 - $4.58 $1.57 Million - $2.13 Million
463,994 Added 48.04%
1,429,850 $6.03 Million
Q3 2023

Nov 16, 2023

BUY
$4.28 - $6.57 $671,514 - $1.03 Million
156,896 Added 19.39%
965,856 $4.17 Million
Q2 2023

Aug 14, 2023

SELL
$5.9 - $6.95 $516,527 - $608,451
-87,547 Reduced 9.77%
808,960 $5.33 Million
Q1 2023

May 15, 2023

BUY
$6.18 - $7.99 $285,281 - $368,834
46,162 Added 5.43%
896,507 $6.09 Million
Q4 2022

Feb 14, 2023

SELL
$6.87 - $10.96 $38,643 - $61,650
-5,625 Reduced 0.66%
850,345 $6.28 Million
Q3 2022

Nov 15, 2022

SELL
$9.44 - $11.76 $1.66 Million - $2.06 Million
-175,525 Reduced 17.02%
855,970 $8.46 Million
Q2 2022

Aug 15, 2022

BUY
$9.31 - $11.84 $8.85 Million - $11.3 Million
950,812 Added 1178.45%
1,031,495 $11.2 Million
Q1 2022

May 16, 2022

BUY
$10.84 - $16.55 $874,603 - $1.34 Million
80,683 New
80,683 $913,000
Q4 2021

Feb 14, 2022

SELL
$15.69 - $21.14 $1.37 Million - $1.85 Million
-87,493 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$15.35 - $21.27 $2.06 Million - $2.85 Million
-134,141 Reduced 60.52%
87,493 $1.5 Million
Q2 2021

Aug 16, 2021

SELL
$15.71 - $21.51 $7.65 Million - $10.5 Million
-486,854 Reduced 68.72%
221,634 $4.77 Million
Q1 2021

May 17, 2021

SELL
$13.42 - $20.28 $576,402 - $871,046
-42,951 Reduced 5.72%
708,488 $10.6 Million
Q4 2020

Feb 16, 2021

BUY
$9.77 - $13.81 $2.96 Million - $4.19 Million
303,295 Added 67.68%
751,439 $9.87 Million
Q3 2020

Nov 16, 2020

BUY
$9.32 - $12.02 $4.18 Million - $5.39 Million
448,144 New
448,144 $4.33 Million
Q2 2019

Aug 13, 2019

SELL
$13.37 - $18.85 $172,473 - $243,165
-12,900 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$17.59 - $31.05 $1.49 Million - $2.63 Million
-84,635 Reduced 86.77%
12,900 $237,000
Q4 2018

Feb 14, 2019

BUY
$18.97 - $31.47 $1.17 Million - $1.95 Million
61,910 Added 173.78%
97,535 $2.55 Million
Q3 2018

Nov 14, 2018

SELL
$18.25 - $23.0 $103,568 - $130,525
-5,675 Reduced 13.74%
35,625 $818,000
Q2 2018

Aug 14, 2018

BUY
$13.95 - $19.15 $89,419 - $122,751
6,410 Added 18.37%
41,300 $787,000
Q1 2018

May 15, 2018

BUY
$14.05 - $20.2 $174,220 - $250,480
12,400 Added 55.14%
34,890 $588,000
Q4 2017

Feb 13, 2018

BUY
$12.85 - $18.1 $288,996 - $407,069
22,490
22,490 $342,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $288M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.